Molecular Tumor Boards, Pathways, and Precision Medicine
Originally presented at HOPA's 14th Annual Conference, March 2018.
Precision medicine is an emerging field that uses genomic sequencing to direct treatment options for patients. Oncology clinical pharmacists have been at the forefront of precision medicine efforts since their inception, and molecular tumor boards, often led by clinical pharmacists, are leading care optimization. This session aims to provide insight into current and emerging practices in molecular tumor boards across the nation. Key topics will include assessment of tumor somatic mutations, germline mutations, and the role of the clinical pharmacist in directing therapy. Real-life case and outcomes will be presented to illustrate this emerging field. This session is geared to practitioners of all levels, and researchers and administrators will gain valuable insights into precision medicine.
Speakers
Cyrine Eliana Haidar, PharmD BCOP BCPS; Patrick Kiel, PharmD BCOP BCPS; Jill Kolesar, PharmD MS BCPS FCCP; Christine Walko, PharmD BCOP FCCP
Activity type
Patient Management & Therapeutics
Accreditation Statement
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .15 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021
Member: $25
Non-Member: $35
